You are here > Biopharmaceutical Glossaries & Taxonomies Homepage > Therapeutic indications > Cancer overview
Cancer & Immuno-Oncology overview glossary & taxonomy
SCOPE
NOTE Cancer
and
oncology
include immuno-oncology, liquid biopsies, CAR T Cell therapies,
circulating tumor cells, neoantigen targeted therapies, NK Natural Killer
Cells based cancer immunotherapies, cancer vaccines, oncolytic virus
immunotherapies, tumor microenvironment
Related glossaries &
taxonomies
Cancer
& Immuno-oncology
Molecular
Diagnostics
Molecular Medicine
Adoptive T Cell Therapy
August 11-12., 2020
Boston, MA
Efforts
to engineer CAR Ts, NKs, TCRs, and TILs with greater precision, safety
profiles, and efficacy are leading to the second generation of improved
adoptive cell therapies. With multiple engineered receptors already making
preclinical impact, many biotech and pharma companies are preparing for
the next wave of clinical trials. The end goal is still the same: improved
patient outcomes. However, there remain technical considerations and
translational challenges relating to cell therapy development,
manufacturing practicability, clinical trial approaches, cell quality and
persistence, and patient management
https://www.immuno-oncologysummit.com/T-Cell/
antibodies
cancer therapy:
Antibodies for Cancer Therapy
Driving Breakthrough Therapies
May 4-5, 2020 Boston MA
Program
Antibodies have become the most sought-after tools in drug discovery, with
bispecific antibodies and cell engagers leading the pack of new
constructs. New insights on the tumor microenvironment and the microbiome
can determine how successful a therapeutic strategy will be, and new
imaging tools will help improve delivery of antibody drugs
ANTIBODY DRUG CONJUGATES
2020 May 6-7 BOSTON MA A
successful ADC requires the combination of the right target, right
antibody, right linker and the right payload. Getting it right can create
ADCs that have the potential to become a life-saving medicine for many
diseases, especially cancer.
https://www.pegsummit.com/Antibody-Drug-Conjugates/ Bispecific Antibodies to the Clinic for Oncology Advancing Bispecific Antibodies and Combination Therapy to the Clinic Creating the Killer Combo May 6-7, 2020 BOSTON MA / The development of bispecific antibodies is one of the hottest areas in biologic research at the moment and their advancement to preclinical and clinical development will determine what the future of this area will look like. https://www.pegsummit.com/Bispecific-Antibodies-For-Oncology
Bispecific Antibodies for Cancer Immunotherapy
August 10-12 2020 Boston, MA
|
CAR T-cell therapy: A
type of treatment in which a patient's T cells (a type of immune system
cell) are changed in the laboratory so they will attack cancer cells. T
cells are taken from a patient’s blood. Then the gene for a special
receptor that binds to a certain protein on the patient’s cancer cells is
added in the laboratory. The special receptor is called a chimeric antigen
receptor (CAR). Large numbers of the CAR T cells are grown in the
laboratory and given to the patient by infusion. CAR T-cell therapy is
being studied in the treatment of some types of cancer. Also called
chimeric antigen receptor T-cell therapy. NCI Dictionary of Cancer Terms
https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=771302 Circulating Tumor Cells March 2-4, 2020 • San Francisco, CA https://www.triconference.com/Circulating-Tumor-Cells | Circulating tumor cells and cell-free tumor DNA have dominated the headlines for the past decade and presently new liquid biopsy tests are entering the clinic. These will enable improved diagnosis of cancer, early detection, and a new era of companion diagnostics for therapy selection, monitoring, predicting outcomes, and measuring the risk of recurre Emerging Immuno-Oncology Targets August 11-12, 2020 Boston, MA | While cancer immunotherapy has made a giant leap in the past five years, the majority of therapies at advanced stages of development are clustered in a similar target space. The increased investment in immuno-oncology has created an urgent opportunity to discover and populate new target spaces that either present new classes of immunotherapies or can be used in combination with existing products. https://www.immuno-oncologysummit.com/Immuno-Oncology-Targets/ Engineering Next-Generation Cancer Immunotherapies January 20-21, 2020 • San Diego, CA https://www.chi-peptalk.com/cancer-immunotherapies/ Based on the clinical successes of checkpoint inhibitors, the industry is now directing its attention to combination treatments, single agent therapeutics with multiple modes of action, confronting resistance mechanisms, reducing toxicity and the persistent challenge of solid tumors. immuno-oncology IO: As our understanding of tumor immunology has advanced, immuno-oncology has made unprecedented progress in improving the outcomes for cancer patients. Immuno-Oncology Summit 2020 Aug 10-14 https://www.immuno-oncologysummit.com/
Immuno-Oncology Biomarkers & Companion Diagnostics
Predicting Response and Guiding Patient
Selection in IO Trials and Patient Care MARCH 2-4, 2020 San Francisco CA
Recent advances in cancer immunotherapy have
generated excitement across all fields of oncology. However, the field is
still experiencing a lack of predictive biomarkers and patient selection
remains difficult. Challenges in discovering predictive biomarkers for
cancer immunotherapy involve multiple cell types, multiple mechanisms of
T-cell regulation, genetic heterogeneity of tumors, immune components. https://www.triconference.com/Preclinical-Immuno-Oncology-Biomarkers
immunotherapy: A type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases. Some types of immunotherapy only target certain cells of the immune system. Others affect the immune system in a general way. Types of immunotherapy include cytokines, vaccines, bacillus Calmette-Guerin (BCG), and some monoclonal antibodies. NCI Dictionary of Cancer terms https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunotherapy
Obtaining material for pathological examination and analysis, from bodily fluids. Material retrieved includes CELL-FREE NUCLEIC ACIDS; CELL-DERIVED MICROPARTICLES; EXOSOMES; CIRCULATING NEOPLASM CELLS; and other circulating cells and CELLULAR STRUCTURES. MeSH Year introduced: 2018
Liquid biopsy enabling
technologies
August 25-26, 2020 Washington, DC
https://www.nextgenerationdx.com/circulating-tumor-cells/ | The
technologies in the liquid biopsy field have been maturing rapidly and are
on their path to revolutionize the management of cancer patients. However,
in the increasingly crowded landscape of all the diagnostic approaches, it
can be overwhelming to identify the key technologies that are showing
promises and have
Neoantigens:
A neoantigenic determinant is an epitope on
a neoantigen,
which is a newly formed antigen that
has not been previously recognized by the immune system.[1] Neoantigens
are often associated with tumor
antigens
and are found in oncogenic cells.[2] Neoantigens
and, by extension, neoantigenic determinants can be formed when a protein
undergoes further modification within a biochemical pathway such as glycosylation, phosphorylation or proteolysis.
This, by altering the structure of the protein, can produce new epitopes
that are called neoantigenic determinants as they give rise to new antigenic
determinants.
Wikipedia
https://en.wikipedia.org/wiki/Neoantigenic_determinant
Tumor antigen: an antigenic substance produced in tumor cells, i.e., it triggers an immune response in the host. Tumor antigens are useful tumor markers in identifying tumor cells with diagnostic tests and are potential candidates for use in cancer therapy. Wikipedia accessed 2018 August 8 https://en.wikipedia.org/wiki/Tumor_antigen tumor microenvironment (TME): Targeting the Tumour Microenvironment, Nov 18-19 2019, Lisbon Portugal innovations for enhancing the immune anti-tumour response and overcoming inhibitory factors. It is becoming clear that many immunosuppressive mechanisms are at work. The checkpoint inhibitors are not living up to expectations, and for these and other antagonists to be effective, it is necessary to control Tregs and manipulate myeloid-derived and other suppressor cells in the tumour microenvironment (TME). The leaders in the field are also paying attention to the role of cytokines and the importance of Fc-engagement for effective targeting. https://www.pegsummiteurope.com/tumour-microenvironment
tumoroid: An aggregate of cancer cells
Cancer Resources
NCI National Cancer Institute, Dictionary of
cancer terms, about 8,800 terms. http://www.cancer.gov/dictionary/
IUPAC definitions are reprinted with the permission of the International Union of Pure and Applied Chemistry. |
Contact
| Privacy Statement |
Alphabetical
Glossary List | Tips & glossary
FAQs | Site Map